FMI: Family Motivational Intervention in Schizophrenia
Study Details
Study Description
Brief Summary
Cannabis use by people with schizophrenia is associated with family distress and poor clinical outcomes. Therefore, an Family Motivational Intervention (FMI) was developed to help parents to motivate their child with a diagnoses of recent-onset schizophrenia to reduce cannabis use.
In a single-blind randomised clinical trail with 75 patients with the diagnosis of schizophrenia, parents will be assigned to either FMI or to routine care. Assessments will be conducted at baseline and at a 10- and 22-month follow-up. The study hypothesis is that FMI will be more effective than routine care in reducing (a) cannabis use in patients and (b) distress and sense of burden in parents.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Family Motivational Intervention An intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing. |
Behavioral: Family Motivational Intervention
A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
|
Active Comparator: Routine care for parents Routine care for parents consisting of 2 sessions psycho-education and individual support |
Behavioral: Family Motivational Intervention
A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
|
Outcome Measures
Primary Outcome Measures
- Cannabis use in patients with a diagnosis of recent-onset schizophrenia [Baseline (before the start of the intervention)]
- Cannabis use in patients with a diagnosis of recent-onset schizophrenia [10-month follow-up (3 months after the intervention has ended)]
- Cannabis use in patients with a diagnosis of recent-onset schizophrenia [22-month follow-up (15 months after the intervention has ended)]
Secondary Outcome Measures
- Medication adherence in patients with a diagnosis of recent-onset schizophrenia [Baseline (before the start of the intervention)]
- Medication adherence in patients with a diagnosis of recent-onset schizophrenia [10-month follow-up (3 months after the intervention has ended)]
- Medication adherence in patients with a diagnosis of recent-onset schizophrenia [22-month follow-up (15 months after the intervention has ended)]
- Quality of life in patients with recent-onset schizophrenia [Baseline (before the start of the intervention)]
- Quality of life in patients with recent-onset schizophrenia [10-month follow-up (3 months after the intervention has ended)]
- Quality of life in patients with recent-onset schizophrenia [22-month follow-up (15 months after the intervention has ended)]
- Stress in parents due to caring for a child with recent-onset schizophrenia [Baseline (before the start of the intervention)]
- Stress in parents due to caring for a child with recent-onset schizophrenia [10-month follow-up (3 months after the intervention has ended)]
- Stress in parents due to caring for a child with recent-onset schizophrenia [22-month follow-up (15 months after the intervention has ended)]
- Expressed emotion in parents of patients with recent-onset schizophrenia [Baseline (before the start of the intervention)]
- Expressed emotion in parents of patients with recent-onset schizophrenia [10-month follow-up (3 months after the intervention has ended)]
- Expressed emotion in parents of patients with recent-onset schizophrenia [22-month follow-up (15 months after the intervention has ended)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Clinical diagnosis of schizophrenia or psychotic-related disorder
-
Onset of schizophrenia or related disorder within pervious the 10 years
-
Cannabis use at least 2 days per week in the 3 months prior to the assessment
-
Antipsychotic medication in prescribed or indicated
-
At least 10 hours of contact with the parents each week in the last month
Exclusion Criteria:
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Academic Medical Center | Amsterdam | North Holland | Netherlands | 1066 DP |
Sponsors and Collaborators
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Investigators
- Study Director: Gerard Schippers, Prof. dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Principal Investigator: Don Linszen, Prof.dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Study Chair: Lieuwe de Haan, Dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study Documents (Full-Text)
None provided.More Information
Publications
- Grant 100003014